Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 9, 2025 (2 years ago)

Hemopropin Ointment

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Hemopropin Ointment, Lanolin 17.76% and Petrolatum 71.2%, Net Wt. 0.7 oz (20g) tubes, Manufactured by: Apipharma d.o.o, Croatia, Distributed by: Apipharma, LLC, Tempe, AZ UPC 3 858882 103534 and UPC 3 858882 101318

Recalling firm
Apipharma
Origin
N/A, Croatia
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0375-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other recalls by Apipharma

All 2025 recalls

Other cgmp deviation recalls from 2025

All cgmp deviation recalls
Class II · Moderate risk

TPN bag (patient specific)

Incorrect Product Formulation: product did not contain insulin as listed in the label.

Ongoing cGMP deviation Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles D-0524-2026
Class II · Moderate risk

Toothpaste: a) COLGATE

CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.

Ongoing cGMP deviation Gold Star Distribution INC D-0287-2026
Class II · Moderate risk

Deodorant: a) Axe

CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.

Ongoing cGMP deviation Gold Star Distribution INC D-0286-2026